Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men: A Randomized, Double-Blind, Placebo-Controlled Crossover-Design Study.

Muensterman ET, Jaynes HA, Sowinski KM, Overholser BR, Shen C, Kovacs RJ, Tisdale JE.

Circulation. 2019 Sep 24;140(13):1127-1129. doi: 10.1161/CIRCULATIONAHA.119.041395. Epub 2019 Sep 23. No abstract available.

PMID:
31545681
2.

Progesterone pretreatment reduces the incidence of drug-induced torsades de pointes in atrioventricular node-ablated isolated perfused rabbit hearts.

Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Kovacs RJ.

J Cardiovasc Electrophysiol. 2019 Jun;30(6):941-949. doi: 10.1111/jce.13942. Epub 2019 Apr 21.

PMID:
31006943
3.

Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.

JACC Clin Electrophysiol. 2016 Dec;2(7):765-774. doi: 10.1016/j.jacep.2016.02.015.

4.

Educational Background and Academic Rank of Faculty Members within US Schools of Pharmacy.

Assemi M, Hudmon KS, Sowinski KM, Corelli RL.

Am J Pharm Educ. 2016 May 25;80(4):61. doi: 10.5688/ajpe80461.

5.

Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.

Ghannoum M, Yates C, Galvao TF, Sowinski KM, Vo TH, Coogan A, Gosselin S, Lavergne V, Nolin TD, Hoffman RS; EXTRIP workgroup.

Clin Toxicol (Phila). 2014 Dec;52(10):993-1004. doi: 10.3109/15563650.2014.973572. Epub 2014 Oct 30. Review.

6.

Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology.

Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, Kanji S, Mowry JB, Calello DP, Hoffman RS, Gosselin S, Nolin TD, Goldfarb DS, Burdmann EA, Dargan PI, Decker BS, Hoegberg LC, Maclaren R, Megarbane B, Sowinski KM, Yates C, Mactier R, Wiegand T, Ghannoum M.

Semin Dial. 2014 Jul-Aug;27(4):407-14. doi: 10.1111/sdi.12251. Epub 2014 May 29. Review.

7.

The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.

Pergolizzi JV Jr, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R Jr, Summers KH.

J Manag Care Spec Pharm. 2014 May;20(5):467-76.

8.

Extracorporeal treatment for tricyclic antidepressant poisoning: recommendations from the EXTRIP Workgroup.

Yates C, Galvao T, Sowinski KM, Mardini K, Botnaru T, Gosselin S, Hoffman RS, Nolin TD, Lavergne V, Ghannoum M; EXTRIP workgroup.

Semin Dial. 2014 Jul-Aug;27(4):381-9. doi: 10.1111/sdi.12227. Epub 2014 Apr 9. Review.

9.

Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.

Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, Mueller BA.

Antimicrob Agents Chemother. 2014;58(3):1320-6. doi: 10.1128/AAC.02090-12. Epub 2013 Dec 9.

10.

Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments.

Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR.

Am J Kidney Dis. 2013 Jun;61(6):1046-8. doi: 10.1053/j.ajkd.2013.02.358. Epub 2013 Apr 4. No abstract available.

11.

Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.

Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, Mueller BA.

Pharmacotherapy. 2012 Dec;32(12):1061-9. doi: 10.1002/phar.1151.

12.

Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis.

Decker BS, Mohamed AN, Chambers M, Kraus MA, Moe SM, Sowinski KM.

Am J Nephrol. 2012;36(2):144-50. doi: 10.1159/000339937. Epub 2012 Jul 18.

13.

Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.

Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ.

J Clin Pharmacol. 2012 Sep;52(9):1296-305. doi: 10.1177/0091270011416939. Epub 2011 Nov 1.

14.

The influence of an elective introductory clinical research course on pharmacy student interest in pursuing research-based careers.

Overholser BR, Foster DR, Henry JR, Plake KS, Sowinski KM.

Am J Pharm Educ. 2010 Nov 10;74(9):165.

15.

Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.

Cheatham SC, Shea KM, Healy DP, Humphrey ML, Fleming MR, Wack MF, Smith DW, Sowinski KM, Kays MB.

Int J Antimicrob Agents. 2011 Jan;37(1):46-50. doi: 10.1016/j.ijantimicag.2010.08.016. Epub 2010 Nov 11.

PMID:
21074370
16.

Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.

Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA.

Crit Care Med. 2011 Jan;39(1):19-25. doi: 10.1097/CCM.0b013e3181fa36fb. Erratum in: Crit Care Med. 2011 May;39(5):1247.

PMID:
20890189
17.

Cefuroxime pharmacokinetics in pediatric cardiovascular surgery patients undergoing cardiopulmonary bypass.

Knoderer CA, Saft SA, Walker SG, Rodefeld MD, Turrentine MW, Brown JW, Healy DP, Sowinski KM.

J Cardiothorac Vasc Anesth. 2011 Jun;25(3):425-30. doi: 10.1053/j.jvca.2010.07.022. Epub 2010 Sep 23.

PMID:
20864357
18.

The essential research curriculum for doctor of pharmacy degree programs.

American College of Clinical Pharmacy, Lee MW, Clay PG, Kennedy WK, Kennedy MJ, Sifontis NM, Simonson D, Sowinski KM, Taylor WJ, Teply RM, Vardeny O, Welty TE.

Pharmacotherapy. 2010 Sep;30(9):966. doi: 10.1592/phco.30.9.966.

19.

The influence of progesterone alone and in combination with estradiol on ventricular action potential duration and triangulation in response to potassium channel inhibition.

Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM.

J Cardiovasc Electrophysiol. 2011 Mar;22(3):325-31. doi: 10.1111/j.1540-8167.2010.01869.x. Epub 2010 Aug 19.

PMID:
20731743
20.

Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.

Decker BS, Kays MB, Chambers M, Kraus MA, Moe SM, Sowinski KM.

Clin J Am Soc Nephrol. 2010 Nov;5(11):1981-7. doi: 10.2215/CJN.03450410. Epub 2010 Jul 8.

21.

Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.

Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.

Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.

PMID:
19809009
22.

Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.

Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.

Int J Antimicrob Agents. 2009 Nov;34(5):429-33. doi: 10.1016/j.ijantimicag.2009.07.004. Epub 2009 Sep 1.

PMID:
19726163
23.

Pharmacy practice research careers.

American College of Clinical Pharmacy, Smith JA, Olson KL, Sowinski KM.

Pharmacotherapy. 2009 Aug;29(8):1007-11. doi: 10.1592/phco.29.8.1007. No abstract available.

PMID:
19637956
24.

Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.

Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ.

Pharmacotherapy. 2008 Dec;28(12):1461-70. doi: 10.1592/phco.28.12.1461.

PMID:
19025427
25.

Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.

Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM.

Pharmacotherapy. 2008 Jun;28(6):691-8. doi: 10.1592/phco.28.6.691.

PMID:
18503396
26.

Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing.

Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA.

Clin J Am Soc Nephrol. 2008 Mar;3(2):355-61. doi: 10.2215/CJN.02920707. Epub 2008 Jan 30.

27.

Biostatistics primer: part 2.

Overholser BR, Sowinski KM.

Nutr Clin Pract. 2008 Feb;23(1):76-84.

PMID:
18203967
28.

Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions.

Foster DR, Sowinski KM, Chow HH, Overholser BR.

Ther Drug Monit. 2007 Dec;29(6):835-42.

PMID:
18043484
29.

Biostatistics primer: part I.

Overholser BR, Sowinski KM.

Nutr Clin Pract. 2007 Dec;22(6):629-35. Review. Erratum in: Nutr Clin Pract. 2009 Dec;24(6):741.

PMID:
18042950
30.

Drug dosing considerations in alternative hemodialysis.

Decker BS, Mueller BA, Sowinski KM.

Adv Chronic Kidney Dis. 2007 Jul;14(3):e17-26. Review.

PMID:
17603971
31.

Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.

Cochran BG, Sowinski KM, Fausel C, Overholser BR.

Am J Health Syst Pharm. 2007 Jul 1;64(13):1410-4.

PMID:
17592007
32.

Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease.

Overholser BR, Brophy DF, Sowinski KM.

Ther Drug Monit. 2006 Dec;28(6):807-12.

PMID:
17164698
33.

Preparation for the pharmacotherapy specialty certification examination: are question cues enough?

Sowinski KM, Wright JM; 2006 Specialty Council on Pharmacotherapy, Board of Pharmaceutical Specialties.

Pharmacotherapy. 2006 Nov;26(11):1675-6; discussion 1676-7. No abstract available.

PMID:
17064217
34.

Gatifloxacin pharmacokinetics in healthy men and women.

Zhang X, Overholser BR, Kays MB, Sowinski KM.

J Clin Pharmacol. 2006 Oct;46(10):1154-62.

PMID:
16988204
35.

The state of science and research in clinical pharmacy.

American College of Clinical Pharmacy Research Affairs Committee, Fagan SC, Touchette D, Smith JA, Sowinski KM, Dolovich L, Olson KL, Cheang KI, Kolesar JM, Crismon ML.

Pharmacotherapy. 2006 Jul;26(7):1027-40. No abstract available.

PMID:
16803427
36.

Effect of ensure on the oral bioavailability of gatifloxacin in healthy volunteers.

Kays MB, Overholser BR, Lagvankar S, Goldman M, Sowinski KM.

Pharmacotherapy. 2005 Nov;25(11):1530-5.

PMID:
16232015
37.

Pharmacokinetics of intravenously administered levofloxacin in men and women.

Overholser BR, Kays MB, Lagvankar S, Goldman M, Mueller BA, Sowinski KM.

Pharmacotherapy. 2005 Oct;25(10):1310-8.

PMID:
16185174
38.

Subcutaneous terbutaline use in CKD to reduce potassium concentrations.

Sowinski KM, Cronin D, Mueller BA, Kraus MA.

Am J Kidney Dis. 2005 Jun;45(6):1040-5.

PMID:
15957133
39.

Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure.

Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC, Clark DO, Stroupe KT, Wu J, Deer MM, Bruner-England TE, Sowinski KM, Smith FE, Oldridge NB, Gradus-Pizlo I, Murray LL, Brater DC, Weinberger M.

Am J Geriatr Pharmacother. 2004 Mar;2(1):53-65.

PMID:
15555479
40.

Sex-related differences in the pharmacokinetics of oral ciprofloxacin.

Overholser BR, Kays MB, Forrest A, Sowinski KM.

J Clin Pharmacol. 2004 Sep;44(9):1012-22.

PMID:
15317829
41.
42.

Ofloxacin clearance during continuous hemofiltration.

Mueller BA, Pasko DA, Sowinski KM.

Am J Kidney Dis. 2003 Dec;42(6):1326-7; author reply 1327-8. No abstract available.

PMID:
14655211
43.

Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.

Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM.

Am J Kidney Dis. 2003 Dec;42(6):1253-9.

PMID:
14655198
44.

Determination of gatifloxacin in human serum and urine by high-performance liquid chromatography with ultraviolet detection.

Overholser BR, Kays MB, Sowinski KM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Dec 5;798(1):167-73.

PMID:
14630373
45.

Higher renal replacement therapy dose delivery influences on drug therapy.

Mueller BA, Pasko DA, Sowinski KM.

Artif Organs. 2003 Sep;27(9):808-14.

46.

Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.

Sowinski KM, Lucksiri A, Kays MB, Scott MK, Mueller BA, Hamburger RJ.

Am J Kidney Dis. 2003 Aug;42(2):342-9.

PMID:
12900817
47.

CAHP-210 dialyzer influence on intra-dialytic vancomycin removal.

Lucksiri A, Scott MK, Mueller BA, Hamburger RJ, Sowinski KM.

Nephrol Dial Transplant. 2002 Sep;17(9):1649-54.

PMID:
12198218
49.

Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.

Goldstein SL, Murry DJ, May S, Aleksic A, Sowinski KM, Blaney S.

Pediatr Nephrol. 2001 Dec;16(12):1015-8.

PMID:
11793091
50.

Supplemental Content

Loading ...
Support Center